Commercial
Advanced Search
  
MPNewsFlashTopicPub
MPPurposePub
  
  
  
  
6/14/2022
Preventive Coverage of Colonoscopy Following a Positive Non-invasive Stool-based Screening Test or Direct Visualization Test for Independence Commercial Members
The purpose of this communication is to convey our current coverage position regarding coverage of a screening colonoscopy following a positive non-invasive stool-based screening test or direct visualization test for Independence Commercial members. 

0.1Preventive Coverage of Colonoscopy Following a Positive Non-invasive Stool-based Screening Test or Direct Visualization Test for Independence Commercial Members8e53383e-514d-4558-8868-d69787ca978a
5/31/2022
Preventive Coverage of FDA-Approved Contraceptive Mobile Applications for Independence Commercial Members
The purpose of this communication is to provide notice regarding the preventive coverage of FDA-approved contraceptive mobile applications​​ for Independence Commercial members effective June 1, 2022. 
0.1Preventive Coverage of FDA-Approved Contraceptive Mobile Applications for Independence Commercial Membersa9a84ad3-aaa7-45ce-b785-63633b8906bb
5/2/2022
Coverage of the COVID-19 Vaccination for Independence Commercial Members (Updated May 2, 2022)

The purpose of this communication is to provide notice regarding information and procedure codes related to the coverage of SARS-CoV-2 (Corona​virus Disease 2019 (COVID-19)) vaccines and administration of the vaccines for Independence Commercial members.

0.1Coverage of the COVID-19 Vaccination for Independence Commercial Members (Updated May 2, 2022)60407faa-658d-4a46-ad97-8910fbf1aec2
3/31/2022
04/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products
The intent of this document is to communicate Medicare Advantage Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 04/01/2022, unless otherwise noted.

For more information related to these services, please refer to specific policies when applicable.​​​​​​


0.104/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products00fd5da3-c5a3-4c49-adf1-5405e7136e9a
3/7/2022
Preventive Coverage of Recombinant zoster vaccine (Shingrix), 15-Valent Pneumococcal Conjugate Vaccine, and 20-Valent Pneumococcal Conjugate Vaccine for Independence Commercial Members
The purpose of this communication is to provide notice regarding the expanded preventive coverage criteria for recombinant zoster vaccine (Shingrix), 15-Valent Pneumococcal Conjugate Vaccine, and 20-Valent Pneumococcal Conjugate Vaccine​​​ for Independence Commercial members effective January 21, 2022.

0.1Preventive Coverage of Recombinant zoster vaccine (Shingrix), 15-Valent Pneumococcal Conjugate Vaccine, and 20-Valent Pneumococcal Conjugate Vaccine for Independence Commercial Membersdd4ceef2-2beb-45cd-9523-7be482ca7a88
2/18/2022
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Commercial Members (Updated February 18, 2022)

The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence commercial members.

0.1Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Commercial Members (Updated February 18, 2022)b7b199d0-3bed-420f-a82b-947fc82bf51f
1/24/2022
Extension of Coverage for Immune Prophylaxis for Respiratory Syncytial Virus (RSV) with palivizumab (Synagis)
The purpose of this communication is to convey notification of coverage of additional doses for palivizumab (Synagis) for the expanded 2021-2022 RSV season.​
0.1Extension of Coverage for Immune Prophylaxis for Respiratory Syncytial Virus (RSV) with palivizumab (Synagis)6b3ee8ba-eb0e-4a98-a0bc-b467099d9746
12/31/2021
ADUHELM™ (aducanumab-avwa) injection for Commercial Members (Updated January 1, 2022)
The purpose of this communication is to provide notification of ​the Company's position for ADUHELM™ (aducanumab-avwa) injection​ for all Commercial Products effective as of June 7, 2021.
0ADUHELM™ (aducanumab-avwa) injection for Commercial Members (Updated January 1, 2022)a9ee4734-cb58-454d-99d3-ec39e3d68714
12/31/2021
Coverage of Speech Therapy Services Performed Through Telemedicine for Independence Commercial Members (Updated January 1, 2022)

The purpose of this communication is to provide notice regarding coverage for speech therapy services performed through telemedicine for our Independence Commercial members during the coronavirus disease 2019 public health emergency.

0.1Coverage of Speech Therapy Services Performed Through Telemedicine for Independence Commercial Members (Updated January 1, 2022) e1cfa675-fd30-49d8-8ebe-5516fbbac4da
12/31/2021
1/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products (Updated January 7, 2022)
The intent of this document ​is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 01/01/2022, unless otherwise noted.
0.11/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products (Updated January 7, 2022)5b4a4df3-2ec7-47ba-b80b-226612429235
10/1/2021
10/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products
The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2021, unless otherwise noted.

For more information related to these services, please refer to specific policies when applicable.​​​​​

0.110/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products490ecf35-0761-440c-b534-a035b758d9eb
4/1/2021
4/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products
The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 4/1/2021, unless otherwise noted.


0.14/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Productsc832c919-e231-49f5-b0dc-09bc2f5e33b7
1/4/2021
1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products
The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Annual Code Update process. 
01/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Productsb976b7b6-ff87-4f04-a559-d2f8805e0586
10/22/2020
Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Commercial Members (Updated April 28, 2022).

The purpose of this document is to communicate the Company's coverage position for Pharmaceutical Treatment of COVID-19 for Independence Commercial members. 



0.1Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Commercial Members (Updated April 28, 2022).f30d8f14-c9b2-43df-baa5-47cd3b6d749b
4/29/2020
Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 (December 15, 2021)
The purpose of this News Article is to provide advance notice regarding direct supervision requirements for Incident to services performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in response to Coronavirus Disease 2019 (COVID-19).
1Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 (December 15, 2021)CC0B8A7BBD74419185258558007CCF61